Status:
RECRUITING
HDV Screening Study
Lead Sponsor:
Grace Lai Hung Wong
Collaborating Sponsors:
Gilead Sciences
Conditions:
Hepatitis D Virus Infection
Eligibility:
All Genders
18+ years
Brief Summary
This is a territory-wide cross-sectional study of all individuals living with HIV/HBV coinfection and HBV-related HCC.
Detailed Description
Chronic hepatitis B virus (HBV) infection remains endemic in Hong Kong with an estimated prevalence of 6.2% in the recent Population Health Survey 2020-2022.1 The estimated prevalence of chronic HBV i...
Eligibility Criteria
Inclusion
- Individuals with HIV infection, i.e. anti-HIV or HIV RNA positive; AND
- Individuals with chronic hepatitis B, i.e. hepatitis B surface antigen (HBsAg) or HBV DNA positive for two times at least 6 months apart; AND
- Aged 18 years old or above.
- Written or verbal consent obtained
Exclusion
- Refusal to consent
- Age \< 18 years
Key Trial Info
Start Date :
February 15 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 17 2029
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT06889805
Start Date
February 15 2025
End Date
February 17 2029
Last Update
March 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Chinese University of Hong Kong
Hong Kong, Hong Kong